Juliana Tonini Mesquita

Dr. Juliana Tonini Mesquita

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2015 in Journal of Natural Products
Verified
Journal Article
Closed access
MSMario F. C. Santos
Mario F. C. Santos
PHPhilip M. Harper
Philip M. Harper
DWDavid E. Williams
David E. Williams
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
ÉPÉrika G. Pinto
Érika G. Pinto
RBRoberto G. S. Berlinck
Roberto G. S. Berlinck

5 December 2013 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ARAlexandre Rea
Alexandre Rea
ATAndré Tempone
André Tempone
EPErika G. Pinto
Erika G. Pinto
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
Eliana RodriguesEliana Rodrigues
Eliana Rodrigues
JLJoao Henrique Ghilardi Lago
Joao Henrique Ghilardi Lago
Chagas disease is caused by the parasitic protozoan Trypanosoma cruzi. It has high mortality as well as morbidity rates and usually affects the poorer sections of the population. The development of new, less harmful and more effective drugs is a promising research target, since current standard treatments are highly toxic and administered for long periods. Fractioning of methanol (MeOH) extract of the stem bark of Calophyllum brasiliense (Clusiaceae) resulted in the isolation of the coumarin soulamarin, which was characterized by one- and two-dimensional 1H- and 13C NMR spectroscopy as well as ESI mass spectrometry. All data obtained were consistent with a structure of 6-hydroxy-4-propyl-5-(3-hydroxy-2-methyl-1-oxobutyl)-6″,6″-dimethylpyrane-[2″,3″:8,7]-benzopyran-2-one for soulamarin. Colorimetric MTT assays showed that soulamarin induces trypanocidal effects, and is also active against trypomastigotes. Hemolytic activity tests showed that soulamarin is unable to induce any observable damage to erythrocytes (cmax. = 1,300 µM). The lethal action of soulamarin against T. cruzi was investigated by using amino(4-(6-(amino(iminio)methyl)-1H-indol-2-yl)phenyl)methaniminium chloride (SYTOX Green and 1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i′j′]diquinolizin-18-ium, 9-[4-(chloromethyl)phenyl]-2,3,6,7,12,13,16,17-octahydro-chloride (MitoTracker Red) as fluorimetric probes. With the former, soulamarin showed dose-dependent permeability of the plasma membrane, relative to fully permeable Triton X-100-treated parasites. Spectrofluorimetric and fluorescence microscopy with the latter revealed that soulamarin also induced a strong depolarization (ca. 97%) of the mitochondrial membrane potential. These data demonstrate that the lethal action of soulamarin towards T. cruzi involves damages to the plasma membrane of the parasite and mitochondrial dysfunction without the additional generation of reactive oxygen species, which may have also contributed to the death of the parasites. Considering the unique mitochondrion of T. cruzi, secondary metabolites of plants affecting the bioenergetic system as soulamarin may contribute as scaffolds for the design of novel and selective drug candidates for neglected diseases, mainly Chagas disease. Chagas disease is a parasitic protozoan that affects the poorest population in the world, causing a high mortality and morbidity. As a result of highly toxic and long-term treatments, the discovery of novel, safe and more efficacious drugs is essential. Natural products isolated from plants are commonly used as drug prototypes or precursors to treat parasitic diseases. As part of our investigation of bioactive compounds from Brazilian flora, the present study was undertaken in order to determine the antitrypanosomal effects of the soulamarin, a coumarin isolated from the stem bark of Callophyllum brasiliense (Clusiaceae), against Trypanossoma cruzi. This study moreover investigated the lethal action of soulamarin towards the parasite. Considering the obtained results, secondary metabolites of plants affecting the bioenergetic system as soulamarin may contribute as scaffolds for the design of novel and selective drug candidates for neglected diseases, mainly Chagas disease.

7 September 2015 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
PLPaula S. Lage
Paula S. Lage
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
LMLaís M. Mata
Laís M. Mata
SFSimone O. A. Fernandes
Simone O. A. Fernandes
ECEDUARDO COELHO
EDUARDO COELHO

1 February 2016 in Veterinary Parasitology
Verified
Journal Article
Closed access
MDMariana Costa Duarte
Mariana Costa Duarte
LLLetícia Martins dos Reis Lage
Letícia Martins dos Reis Lage
DLDaniela Pagliara Lage
Daniela Pagliara Lage
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
BSBeatriz Cristina Silveira Salles
Beatriz Cristina Silveira Salles
ECEDUARDO COELHO
EDUARDO COELHO

2 September 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
LMLigia F. Martins
Ligia F. Martins
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
EPErika G. Pinto
Erika G. Pinto
TCThais A. Costa-Silva
Thais A. Costa-Silva
SBSamanta Borborema
Samanta Borborema
ATAndré Tempone
André Tempone

30 May 2017 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
TATatiana Rodrigues Alexandre
Tatiana Rodrigues Alexandre
MLMarta Lopes Lima
Marta Lopes Lima
MGMariana Kolos Galuppo
Mariana Kolos Galuppo
JMJuliana Tonini Mesquita
Juliana Tonini Mesquita
MNMatilia Ana Do Nascimento
Matilia Ana Do Nascimento
ATAndré Tempone
André Tempone
Major drawbacks of the available treatment against Chagas disease (American trypanosomiasis) include its toxicity and therapeutic inefficiency in the chronic phase of the infection, which makes it a concern among neglected diseases. Therefore, the discovery of alternative drugs for treating chronic Chagas disease requires immediate action. In this work, we evaluated the mushroom Pleurotus salmoneostramineus in the search for potential antiparasitic compounds. Fruit bodies of the basidiomycete Pleurotus salmoneostramineus were triturated and submitted to organic solvent extraction. After liquid-liquid partition of the crude extract, three fractions were obtained and the bioguided fractionation study was conducted to isolate the active metabolites. The elucidation of the chemical structure was performed using GC-MS and NMR techniques. The biological assays for antiparasitic activity were carried out using trypomastigotes of Trypanosoma cruzi and murine macrophages for mammalian cytotoxicity. The mechanism of action of the isolated compound used different fluorescent probes to evaluate the plasma membrane permeability, the potential of the mitochondrial membrane and the intracellular levels of reactive oxygen species (ROS). The most abundant fraction showing the antiparasitic activity was isolated and chemically elucidated, confirming the presence of ergosterol. It showed anti-Trypanosoma cruzi activity against trypomastigotes, with an IC50 value of 51.3 μg/mL. The compound demonstrated no cytotoxicity against mammalian cells to the maximal tested concentration of 200 μg/mL. The mechanism of action of ergosterol in Trypanosoma cruzi trypomastigotes resulted in permeabilization of the plasma membrane, as well as depolarization of mitochondrial membrane potential, leading to parasite death. Nevertheless, no increase in ROS levels could be observed, suggesting damages to plasma membrane rather than an induction of oxidative stress in the parasite. The selection of naturally antiparasitic secondary metabolites in basidiomycetes, such as ergosterol, may provide potential scaffolds for drug design studies against neglected diseases.